Anthropic pushes Claude toward drug discovery

Anthropic expands Claude beyond the chatbot to target biomedical research

Anthropic is seeking to move Claude beyond the now-familiar framework of the general-purpose conversational assistant. According to information reported by The Verge in an article titled “Anthropic wants to develop its own drugs”, the company is introducing Claude Science, a work environment designed for researchers, with a clear ambition: to put AI to work for experimental science and, ultimately, drug discovery.

The move is significant because it shifts Anthropic’s center of gravity. Until now, the company was mainly identified with its language models, its competition with OpenAI, Google, or Meta, and its positioning on AI safety. With Claude Science, it is moving onto much more vertical ground, where value is no longer measured only in answer quality, inference speed, or user experience, but in the ability to help scientific teams generate hypotheses, connect complex corpora, and accelerate costly research cycles.

The issue goes far beyond a simple product launch. Drug discovery is one of the most coveted markets in applied AI. It concentrates considerable R&D budgets, long timelines, a gigantic documentary mass, and strong pressure to improve scientific productivity. For a player like Anthropic, succeeding in inserting itself into this value chain would mean turning Claude into research infrastructure, and no longer just a conversational interface.

According to The Verge, the offering relies on the aggregation of scientific literature, data, and reasoning capabilities. Put differently, Anthropic is offering a building block that tries to bring together three dimensions often separated in existing tools: access to information, its structuring, and cognitive assistance in exploring a biomedical problem. That is precisely where today’s battle for AI in science is being fought: less on the brilliant answer to an isolated question than on the ability to support scientific investigative work over time.

This direction is not happening by chance. Since the explosion of generative AI at the end of 2022, all major model labs have been trying to move beyond the logic of the universal chatbot. Conversational interfaces served as a showcase and an adoption channel, but the most robust monetization lies in specialized professional uses. Law, finance, software development, customer service, and research have become priority segments. Science, particularly biology and pharmaceuticals, appears to be one of the next major markets because it combines high informational intensity, needs for intellectual automation, and the promise of major economic returns.

For the French-speaking sector, the stakes are direct. France, Belgium, French-speaking Switzerland, and more broadly Europe have a dense fabric of public laboratories, biotechs, university hospitals, and pharmaceutical groups. If platforms like Claude Science become credible work tools for research, they could influence how teams explore the literature, prioritize experimental avenues, and organize their monitoring. Implicitly, they also raise a question of technological sovereignty: who will provide the AI layers used in strategic scientific workflows?

Claude Science: what The Verge reports about Anthropic’s initiative

The central information reported by The Verge AI is that Anthropic is unveiling Claude Science, described as an AI work environment designed for researchers. The idea is not merely to offer another conversational model, but a work framework that aggregates several types of resources useful for scientific research: academic literature, data, and the reasoning capabilities of the Claude model.

In the very wording of the project, the change in direction is visible. A classic chatbot answers a request. A scientific work environment, by contrast, must support a process: exploring a question, comparing results, connecting publications, formulating hypotheses, identifying blind spots, and possibly preparing the next stage of experimental work. That is the shift Anthropic is trying to make.

The Verge emphasizes the biomedical target and Anthropic’s interest in drug discovery. The title of the original article, deliberately striking, suggests an ambition that goes beyond documentary assistance. It is not just about helping people read scientific papers faster, but about positioning itself in the value chain of pharmaceutical research, one of the areas where AI has for years been presented as a potential accelerator.

The standout point is the combination of document aggregation and reasoning. Biomedical scientific literature is immense, fragmented, constantly growing, and often difficult to synthesize. Thousands of articles, preprints, specialized databases, and experimental results form an informational landscape that even seasoned teams struggle to navigate. Language models promise precisely to act as an orchestration layer: summarize, connect, compare, flag contradictions, suggest avenues.

But the value of a tool like Claude Science depends on its ability to go beyond summarization. In a scientific context, value lies in the rigor of the links established, in the traceability of the sources used, and in the way the tool helps structure an exploration. A researcher does not just expect a fluent answer; they expect a work support that makes it possible to verify the origin of a claim, retrieve relevant papers, and distinguish hypothesis from established evidence.

On this point, Anthropic’s positioning is consistent with the market’s broader evolution. For several months, model and AI tool vendors have been trying to build products more “grounded” in reliable corpora, in order to reduce hallucinations and increase usefulness in professional environments. Scientific research is one of the use cases where this requirement is strongest, because an interpretive error can waste time, steer poor experimental choices, or erode trust in the tool.

The choice of the name Claude Science also reflects a brand strategy. Anthropic is not creating a product entirely separate from Claude; the company is extending its range around an already well-known technological core. It is a way of capitalizing on the recognition of its assistant while opening a vertical front. For potential customers, especially institutional or industrial ones, this continuity may matter: it suggests a platform meant to be adapted by profession rather than a simple one-off demonstration.

The way The Verge presents the announcement suggests that Anthropic wants to be seen as a player in AI for science, not only as a provider of general-purpose models. This is a major strategic shift. In today’s AI economy, being “just” a model is becoming increasingly difficult to defend in the face of price pressure, the multiplication of offerings, and the rise of commoditization. High-value application layers, especially when they touch sectors like healthcare or pharma, offer stronger differentiation prospects.

Why drug discovery has become a central field for AI

If Anthropic is turning to biomedicine, it is also because this field has long been considered one of the most promising for artificial intelligence. Drug discovery relies on long, costly, and risky research cycles. It involves analyzing massive volumes of knowledge, formulating hypotheses about complex biological mechanisms, and selecting avenues that must then be validated experimentally. On paper, it is an almost ideal field for systems capable of exploring large quantities of information and proposing unexpected connections.

It is important, however, to distinguish several promises that are often mixed together in public debate. AI can intervene at different levels: literature research, information extraction, structure modeling, hypothesis generation, target prioritization, assistance with experimental design, or even automation of administrative tasks related to research. Not all these uses have the same maturity, the same level of risk, or the same immediate economic impact.

What Claude Science highlights, as reported by The Verge, primarily concerns the cognitive and informational layer: making better use of literature and data to accelerate biomedical exploration. It is a pragmatic approach. Even before “designing” a drug, there is immense work of reading, synthesis, comparison, and formulation. In many laboratories, this phase absorbs a significant share of human time. A tool capable of streamlining it can therefore have tangible value, even without promising an immediate revolution in chemistry or experimental biology.

Pharma also attracts AI providers for a simple reason: the value of a marginal gain there is potentially enormous. Reducing the time needed to identify an avenue, avoiding duplication of work, or better prioritizing hypotheses can translate into substantial savings and faster time to market, even if these effects are difficult to measure uniformly. AI companies know this, which is why healthcare and biopharma are regularly cited among the most strategic verticals.

The sector is, however, demanding. Tools used in biomedical research must contend with high standards of reliability, documentation, and confidentiality. They fit into organizations where decisions never rest on a single generated answer, but on validation chains, cross-disciplinary expertise, and protocols. A conversational model can help, but it replaces neither trials, nor peer review, nor regulatory evaluation. That is precisely why vertical platforms are so appealing: they seek to make AI compatible with real workflows, rather than imposing a generic interface.

Anthropic’s move thus fits into a deeper trend: generative AI is no longer evaluated only on its ability to impress, but on its ability to integrate into highly constrained professions. In biomedicine, this integration involves access to specialized corpora, better source citation, collaboration tools, and a form of assisted reasoning that remains usable by human experts.

It should also be recalled that the expression “AI for science” covers an important symbolic competition. The players that succeed in demonstrating credible usefulness in research will gain a level of trust capital beyond that of a simple office assistant. Helping write an email or summarize a meeting is useful; helping accelerate biomedical research belongs to a different industrial and political imagination. For Anthropic, establishing itself on this ground means claiming a role in sectors considered strategic for innovation and sovereignty.

Anthropic versus other players: the battle of vertical platforms

The announcement reported by The Verge must be read in the context of intense competition among major AI players. OpenAI, Google, Meta, Microsoft, and several more targeted specialists are all seeking to demonstrate that their models can serve more than generic uses. The question is no longer only “which model answers best?” but “which company is building the best platform for a given profession?”

Anthropic has long cultivated a particular image in this ecosystem. Founded by former OpenAI members, the company has stood out through its discourse on model safety and alignment, as well as through Claude’s rapid rise as a credible alternative to the market’s best-known assistants. But like its rivals, it faces an economic reality: models alone do not always suffice to capture value durably. Vertical uses, integrated into precise professional needs, have become a central axis of differentiation.

From this perspective, Claude Science looks like an attempt to turn Claude into a specialized work platform. This is an evolution seen across the sector. Vendors no longer want only to provide an API or a chat, but environments adapted to complex tasks, with access to sources, tools, and professional contexts. Science is a particularly attractive field because it makes it possible to justify higher prices, institutional contracts, and deep integrations.

Competition is nevertheless fierce, including outside the circle of major general-purpose models. For several years, many companies specializing in AI applied to biology, chemistry, or drug discovery have positioned themselves in this niche. Some focus on molecular modeling, others on biological data analysis, and still others on scientific literature. Anthropic is therefore not arriving on untouched ground; it is arriving with a particular strength, that of a widely publicized language model, but also with the challenge of proving that a generalist player can meet the demands of a highly specialized field.

Anthropic’s bet seems to be that the reasoning and synthesis layer offered by Claude can become a decisive advantage if it is properly connected to the right scientific sources. This is a plausible hypothesis in the short term, because many researchers suffer less from a lack of data than from an excess of information that is difficult to exploit. By contrast, the real differentiation will probably be decided by the quality of integration: depth of corpora, transparency of references, ease of collaboration, management of sensitive data, and the ability to adapt to the workflows of very different laboratories.

The positioning is also skillful on the narrative level. By taking an interest in drug discovery, Anthropic associates itself with a field where AI benefits from a strong symbolic charge. This makes it possible to value Claude in a way other than as a competitor to ChatGPT or Gemini. The comparison changes: we are no longer talking only about an assistant that writes well, but about a system likely to help solve complex scientific problems.

This evolution could weigh on the way large organizations evaluate AI providers. A pharmaceutical company, a research institute, or a university hospital does not necessarily choose its tool based on mainstream popularity. It looks at the ability to meet a precise need, integrate with its documentary constraints, and offer an acceptable level of trust. If Claude Science manages to convince on these criteria, Anthropic could carve out a significant place in a market where purchasing decisions are guided less by hype than by professional usefulness.

Conversely, the initiative also exposes Anthropic to heightened demands. The more a player claims a role in science, the more it is expected to deliver precision, caution, and robustness. The gaps tolerated in consumer uses are much less tolerated in biomedical research. The company will therefore have to demonstrate that its approach is not limited to dressing up a chatbot with a scientific veneer, but that it provides an environment genuinely suited to demanding research practices.

What this changes for the French-speaking research and biotech ecosystem

For France and, more broadly, the European French-speaking sphere, the announcement can be read on several levels. First, it confirms that major American AI providers are now targeting sectors with very high scientific intensity, among which healthcare and biopharma occupy a central place. This directly concerns an ecosystem that brings together public laboratories, universities, research organizations, university hospitals, deeptech start-ups, and pharmaceutical groups present in Europe.

In a country like France, where biomedical research relies on a mix of public and private players, a tool like Claude Science may interest very different profiles: academic researchers confronted with the explosion of publications, scientific monitoring teams, biotech R&D departments, knowledge management functions, or technology transfer structures that need to map a scientific field quickly. The immediate interest is not necessarily to “create a drug with a chatbot,” but to make the exploration of dispersed knowledge more efficient.

The second issue is that of sovereignty. If scientific workflows rely more and more on external AI platforms, the question of technological control becomes sensitive. Who hosts the data? Which corpora are used? What guarantees exist regarding the confidentiality of unpublished results? What governance mechanisms surround the use of these tools in public institutions or in companies subject to strong obligations? The arrival of offerings like Claude Science intensifies these questions, particularly in Europe where sensitivity to regulation and technological dependence is high.

For French-speaking biotechs, the interest may be more tactical. Many of them have limited resources compared with large pharmaceutical groups, but still have to analyze abundant literature, monitor competing advances, and document their programs. A tool capable of aggregating sources and accelerating hypothesis formulation can therefore represent a productivity lever. Still, the tool must be sufficiently reliable, integrate with existing practices, and have a cost compatible with the means of often constrained structures.

On the public research side, the possible adoption of this type of solution will also depend on team culture. Researchers do not necessarily reject AI; many are already experimenting with tools for summarization, translation, monitoring, or writing assistance. But trust is earned slowly, especially in fields where methodological nuance is essential. French-speaking institutions will pay close attention to a tool like Claude Science’s ability to cite its sources correctly, distinguish levels of evidence, and avoid producing speculative claims presented as facts.

Finally, there is a broader industrial dimension. If major models become foundational layers for scientific research, European players will have to decide whether they simply want to consume them, frame them, or build local alternatives and complements. Anthropic’s announcement can therefore also be read as a competitive warning signal: the AI battle is no longer being fought only in office assistants or content generation, but in verticals where considerable scientific and economic value is created.

For French companies in pharmaceuticals, diagnostics, or biotech, this evolution may accelerate a reflection already under way: should certain AI building blocks be brought in-house, should they rely on specialized general-purpose platforms, or should several layers be combined? The answers will vary depending on regulatory constraints, data policies, and the digital maturity of organizations. But one thing is becoming clearer: general-purpose AI players will not be content with selling conversational chats. They want to move up toward the core of professions.

Beyond the announcement, a test for the credibility of AI as scientific infrastructure

The value of Claude Science will not be measured only at launch, but by the way it is used and evaluated by researchers. AI applied to science often suffers from a gap between marketing promise and laboratory reality. Announcements emphasize acceleration, discovery, and transformation. On the ground, teams mainly ask for tools that are reliable, traceable, compatible with their methods, and robust enough not to add noise to an environment already saturated with information.

Anthropic is playing an important hand here. If Claude Science convinces, the company will be able to demonstrate that its models are capable of supporting high-value uses in a field where trust is difficult to obtain. That would strengthen its image as a platform provider, and not just a conversational model. If, on the contrary, the tool remains perceived as an appealing but imprecise interface, it will illustrate the limits of LLMs when they are projected into demanding scientific workflows without sufficient adaptation.

The fact that The Verge links the initiative to Anthropic’s desire to develop “its own drugs” should be understood as the expression of a strategic ambition, not as proof that an integrated pharmaceutical laboratory is already emerging. What is tangible at this stage is the company’s desire to position itself as close as possible to biomedical discovery, where data, literature, and reasoning meet. That is already a considerable change in posture.

Over the longer term, this direction could help redefine the hierarchy of AI players. The companies that succeed best will not necessarily be those that only have the best general-purpose benchmark, but those that know how to turn their models into credible sectoral infrastructures. Scientific research, and even more so drug discovery, constitutes one of the most demanding tests of this hypothesis.

For the French-speaking market, the outlook is twofold. On the one hand, tools like Claude Science can offer a real gain in access to scientific information and in the exploration of complex corpora, which is particularly valuable for teams confronted with the density of global biomedical literature. On the other, their rise reinforces the need for European strategies on data, hosting, interoperability, and independent evaluation of these systems. The issue is not only adopting AI, but knowing under what institutional and industrial conditions it becomes a trusted layer for research.

Anthropic seems to have understood this: AI’s next commercial frontier is not limited to making assistants more pleasant or faster. It consists of entering professions where knowledge is at once abundant, costly, and decisive. Drug discovery checks all those boxes. If Claude Science manages to establish itself as a credible work tool for researchers, then Claude will no longer be just a competitor in the chatbot war. It will become one of the faces of a deeper transformation, that of an AI seeking to install itself at the very heart of scientific production.